{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:07:41Z","timestamp":1791360461914,"version":"4.3.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100018841","name":"Associazione Italiana Ricerca Alzheimer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-01970-4","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:16:24Z","timestamp":1770023784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Blood-based biomarkers for Alzheimer\u2019s disease: influence of kidney function"],"prefix":"10.1186","volume":"18","author":[{"given":"Lorenzo","family":"Gaetani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Toja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Streva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Giombetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo Guido","family":"Torrigiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Paolini Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Chiasserini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"1970_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach TG, Monsell SE, Phillips LE, et al. Accuracy of the clinical diagnosis of alzheimer disease at National Institute on aging alzheimer disease Centers, 2005\u20132010. J Neuropathol Exp Neurol. 2012;71:266\u201373. https:\/\/doi.org\/10.1097\/NEN.0b013e31824b211b.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1970_CR2","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren N, Grinberg LT, Boxer A, et al. Cerebrospinal fluid biomarkers in Autopsy-Confirmed alzheimer disease and frontotemporal Lobar degeneration. Neurology. 2022;98:e1137\u201350. https:\/\/doi.org\/10.1212\/WNL.0000000000200040.","journal-title":"Neurology"},{"key":"1970_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21:66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6.","journal-title":"Lancet Neurol"},{"key":"1970_CR4","doi-asserted-by":"publisher","first-page":"8209","DOI":"10.1002\/alz.14150","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke MM, Anderson M, Ashford JW, et al. Considerations for widespread implementation of blood-based biomarkers of alzheimer\u2019s disease. Alzheimer\u2019s Dementia: J Alzheimer\u2019s Association. 2024;20:8209\u201315. https:\/\/doi.org\/10.1002\/alz.14150.","journal-title":"Alzheimer\u2019s Dementia: J Alzheimer\u2019s Association"},{"key":"1970_CR5","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1002\/alz.14184","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke MM, Anderson M, Ashford JW, et al. Recommendations for clinical implementation of blood-based biomarkers for alzheimer\u2019s disease. Alzheimers Dement. 2024;20:8216\u201324. https:\/\/doi.org\/10.1002\/alz.14184.","journal-title":"Alzheimers Dement"},{"key":"1970_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the global CEO initiative on alzheimer\u2019s disease. Nat Rev Neurol. 2024;20:426\u201339. https:\/\/doi.org\/10.1038\/s41582-024-00977-5.","journal-title":"Nat Rev Neurol"},{"key":"1970_CR7","doi-asserted-by":"publisher","first-page":"e14609","DOI":"10.1002\/alz.14609","volume":"21","author":"F Anastasi","year":"2025","unstructured":"Anastasi F, Fern\u00e1ndez-Lebrero A, Ashton NJ, et al. A head-to-head comparison of plasma biomarkers to detect alzheimer\u2019s disease in a memory clinic. Alzheimer\u2019s Dementia: J Alzheimer\u2019s Association. 2025;21:e14609. https:\/\/doi.org\/10.1002\/alz.14609.","journal-title":"Alzheimer\u2019s Dementia: J Alzheimer\u2019s Association"},{"key":"1970_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/acn3.50972","volume":"7","author":"A Manouchehrinia","year":"2020","unstructured":"Manouchehrinia A, Piehl F, Hillert J, et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol. 2020;7:139\u201343. https:\/\/doi.org\/10.1002\/acn3.50972.","journal-title":"Ann Clin Transl Neurol"},{"key":"1970_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13195-025-01692-z","volume":"17","author":"B Arslan","year":"2025","unstructured":"Arslan B, Brum WS, Pola I, et al. The impact of kidney function on alzheimer\u2019s disease blood biomarkers: implications for predicting amyloid-\u03b2 positivity. Alzheimer\u2019s Res Therapy. 2025;17:48. https:\/\/doi.org\/10.1186\/s13195-025-01692-z.","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"1970_CR10","doi-asserted-by":"publisher","unstructured":"Dittrich A, Ashton NJ, Zetterberg H, et al. Association of chronic kidney disease with plasma NfL and other biomarkers of neurodegeneration. Neurology. 2023;101. https:\/\/doi.org\/10.1212\/WNL.0000000000207419.","DOI":"10.1212\/WNL.0000000000207419"},{"key":"1970_CR11","doi-asserted-by":"publisher","first-page":"20350","DOI":"10.1038\/s41598-020-76990-7","volume":"10","author":"S Akamine","year":"2020","unstructured":"Akamine S, Marutani N, Kanayama D, et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep. 2020;10:20350. https:\/\/doi.org\/10.1038\/s41598-020-76990-7.","journal-title":"Sci Rep"},{"key":"1970_CR12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated Tau 181 and 217 in the community. Nat Med. 2022;28:1398\u2013405. https:\/\/doi.org\/10.1038\/s41591-022-01822-2.","journal-title":"Nat Med"},{"key":"1970_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, et al. Mitigating the associations of kidney dysfunction with blood biomarkers of alzheimer disease by using phosphorylated Tau to total Tau ratios. JAMA Neurol. 2023;80:516\u201322. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199.","journal-title":"JAMA Neurol"},{"key":"1970_CR14","doi-asserted-by":"publisher","first-page":"647783","DOI":"10.3389\/fnins.2021.647783","volume":"15","author":"G Bellomo","year":"2021","unstructured":"Bellomo G, Indaco A, Chiasserini D, et al. Machine learning driven profiling of cerebrospinal fluid core biomarkers in alzheimer\u2019s disease and other neurological disorders. Front NeuroSci. 2021;15:647783. https:\/\/doi.org\/10.3389\/fnins.2021.647783.","journal-title":"Front NeuroSci"},{"key":"1970_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"1970_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.clinph.2007.09.143","volume":"119","author":"M de Carvalho","year":"2008","unstructured":"de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiology: Official J Int Federation Clin Neurophysiol. 2008;119:497\u2013503. https:\/\/doi.org\/10.1016\/j.clinph.2007.09.143.","journal-title":"Clin Neurophysiology: Official J Int Federation Clin Neurophysiol"},{"key":"1970_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314. https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6.","journal-title":"Neurology"},{"key":"1970_CR18","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456\u201377. https:\/\/doi.org\/10.1093\/brain\/awr179.","journal-title":"Brain"},{"key":"1970_CR19","doi-asserted-by":"publisher","unstructured":"Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","DOI":"10.1002\/mds.26424"},{"key":"1970_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mdc3.12808","volume":"6","author":"CA Ross","year":"2019","unstructured":"Ross CA, Reilmann R, Cardoso F, et al. Movement disorder society task force viewpoint: huntington\u2019s disease diagnostic categories. Mov Disorders Clin Pract. 2019;6:541\u20136. https:\/\/doi.org\/10.1002\/mdc3.12808.","journal-title":"Mov Disorders Clin Pract"},{"key":"1970_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1.","journal-title":"Neurology"},{"key":"1970_CR22","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914\u201322. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c47cc2.","journal-title":"Neurology"},{"key":"1970_CR23","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/alz.13687","volume":"20","author":"G Bellomo","year":"2024","unstructured":"Bellomo G, Bayoumy S, Megaro A, et al. Fully automated measurement of plasma A\u03b242\/40 and p-tau181: analytical robustness and concordance with cerebrospinal fluid profile along the alzheimer\u2019s disease continuum in two independent cohorts. Alzheimers Dement. 2024;20:2453\u201368. https:\/\/doi.org\/10.1002\/alz.13687.","journal-title":"Alzheimers Dement"},{"key":"1970_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cca.2008.06.017","volume":"396","author":"H Pottel","year":"2008","unstructured":"Pottel H, Vrydags N, Mahieu B, et al. Establishing age\/sex related serum creatinine reference intervals from hospital laboratory data based on different statistical methods. Clin Chim Acta. 2008;396:49\u201355. https:\/\/doi.org\/10.1016\/j.cca.2008.06.017.","journal-title":"Clin Chim Acta"},{"key":"1970_CR25","doi-asserted-by":"publisher","first-page":"e214446","DOI":"10.1212\/WNL.0000000000214446","volume":"106","author":"F Gasparini","year":"2026","unstructured":"Gasparini F, Valletta M, Vetrano DL, et al. Kidney Function, alzheimer disease blood Biomarkers, and dementia risk in Community-Dwelling older adults. Neurology. 2026;106:e214446. https:\/\/doi.org\/10.1212\/WNL.0000000000214446.","journal-title":"Neurology"},{"key":"1970_CR26","doi-asserted-by":"publisher","first-page":"e70931","DOI":"10.1002\/alz.70931","volume":"21","author":"M Daniilidou","year":"2025","unstructured":"Daniilidou M, \u00d6hlund-Wistbacka U, Hagman G, et al. Enhancing diagnostic precision in alzheimer\u2019s disease: impact of comorbidities on blood biomarkers for clinical integration. Alzheimers Dement. 2025;21:e70931. https:\/\/doi.org\/10.1002\/alz.70931.","journal-title":"Alzheimers Dement"},{"key":"1970_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21\u201342 and A\u03b21\u201340 in the LUMIPULSE automated platform for the detection of alzheimer disease. Alzheimer\u2019s Res Therapy. 2024;16:139. https:\/\/doi.org\/10.1186\/s13195-024-01513-9.","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"1970_CR28","doi-asserted-by":"publisher","first-page":"45897","DOI":"10.1074\/jbc.M407668200","volume":"279","author":"J Ghiso","year":"2004","unstructured":"Ghiso J, Shayo M, Calero M, et al. Systemic catabolism of alzheimer\u2019s A\u03b240 and A\u03b242. J Biol Chem. 2004;279:45897\u2013908. https:\/\/doi.org\/10.1074\/jbc.M407668200.","journal-title":"J Biol Chem"},{"key":"1970_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, et al. CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of alzheimer disease. Ann Clin Transl Neurol. 2016;3:154\u201365. https:\/\/doi.org\/10.1002\/acn3.274.","journal-title":"Ann Clin Transl Neurol"},{"key":"1970_CR30","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"1970_CR31","doi-asserted-by":"publisher","first-page":"e70828","DOI":"10.1002\/alz.70828","volume":"21","author":"S Pahlke","year":"2025","unstructured":"Pahlke S, Kahale LA, Mahinrad S, et al. Blood-based biomarkers for detecting alzheimer\u2019s disease pathology in cognitively impaired individuals within specialized care settings: A systematic review and meta\u2010analysis. Alzheimers Dement. 2025;21:e70828. https:\/\/doi.org\/10.1002\/alz.70828.","journal-title":"Alzheimers Dement"},{"key":"1970_CR32","doi-asserted-by":"publisher","first-page":"e70207","DOI":"10.1002\/dad2.70207","volume":"17","author":"R Perneczky","year":"2025","unstructured":"Perneczky R, Quevenco F-C, Hendrix J, et al. How can alzheimer\u2019s disease blood-based biomarkers reach clinical practice? Alzheimers Dement (Amst). 2025;17:e70207. https:\/\/doi.org\/10.1002\/dad2.70207.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1970_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(25)01294-2","volume":"406","author":"GB Frisoni","year":"2025","unstructured":"Frisoni GB, Hansson O, Nichols E, et al. New landscape of the diagnosis of alzheimer\u2019s disease. Lancet. 2025;406:1389\u2013407. https:\/\/doi.org\/10.1016\/S0140-6736(25)01294-2.","journal-title":"Lancet"},{"key":"1970_CR34","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.mcpro.2023.100629","volume":"22","author":"CE Teunissen","year":"2023","unstructured":"Teunissen CE, Kimble L, Bayoumy S, et al. Methods to discover and validate Biofluid-Based biomarkers in neurodegenerative dementias. Mol Cell Proteom. 2023;22:100629. https:\/\/doi.org\/10.1016\/j.mcpro.2023.100629.","journal-title":"Mol Cell Proteom"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-01970-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-01970-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-01970-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:06:31Z","timestamp":1772582791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-01970-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1970"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-01970-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8007954\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L. Gaetani has participated in advisory boards for and received writing or speaker honoraria and travel grants from Almirall, Biogen, Eisai, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. G. Bellomo received honoraria from Fujirebio and completed paid consultancies for Parkinson\u2019s Foundation. He received travel\/educational grants from Fujirebio and Alzheimer\u2019s Association. D. Chiasserini has nothing to disclose. L. Parnetti served as Member of Advisory Boards for Fujirebio, IBL, Roche, and Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}